Related Experiment Video

Updated: Aug 15, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Current status and challenges of immunotherapy in ALK rearranged NSCLC

Rongbin Qi1, Yingying Yu1, Mo Shen2

  • 1Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.

Frontiers in Oncology
|January 2, 2023
PubMed

Insights

Anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) present challenges with drug resistance and poor immunotherapy response. This review explores immune escape mechanisms and novel combination therapies for ALK-rearranged NSCLC.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Anaplastic lymphoma kinase (ALK) gene rearrangements occur in 5-6% of non-small cell lung cancer (NSCLC) cases.
  • ALK-rearranged NSCLC is initially sensitive to ALK tyrosine kinase inhibitors (TKIs) but often develops drug resistance.
  • Current single-agent immunotherapies show limited efficacy in ALK-rearranged NSCLC.

Conclusions:

  • Understanding immune escape mechanisms is crucial for treating ALK-rearranged NSCLC.
  • Biomarkers can guide therapeutic strategies.
  • Combination immunotherapies represent a promising future direction for ALK-rearranged NSCLC treatment.
Keywords:
ALKNSCLCimmune checkpoint inhibitorimmunotherapyprocess

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

942
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

590

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
622
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K